American Journal of Neuroradiology · 2010 · 90 citations · 22 references
MedicineOncologyRadiologyDiagnostic ImagingMetastasisNeuro-oncologyBrain ImagingBrain MetastasesBrain MetastasisBrain TumorsMagnetic Resonance ImagingMetastatic Brain TumorsBrain Tumor DiagnosisDiagnosis Of Brain MetastasesK-means ClusteringMorphology-based ClassificationMorphometric AnalysisNeuroimaging Of Brain MetastasesTumor Morphology AnalysisTumor Segmentation
BACKGROUND AND PURPOSE: Solitary MET and GBM are difficult to distinguish by using MR imaging. Differentiation is useful before any metastatic work-up or biopsy. Our hypothesis was that MET and GBM tumors differ in morphology. Shape analysis was proposed as an indicator for discriminating these 2 types of brain pathologies. The purpose of this study was to evaluate the accuracy of this approach in the discrimination of GBMs and brain METs. MATERIALS AND METHODS: The dataset consisted of 33 brain MR imaging sets of untreated patients, of which 18 patients were diagnosed as having a GBM and 15 patients, as having solitary metastatic brain tumor. The MR imaging was segmented by using the K-means algorithm. The resulting set of classes (also called "clusters") represented the variety of tissues observed. A morphology-based approach allowed discrimination of the 2 types of tumors. This approach was validated by a leave-1-patient-out procedure. RESULTS: A method was developed for the discrimination of GBMs and solitary METs. Two masses out of 33 were wrongly classified; the overall results were accurate in 93.9% of the observed cases. CONCLUSIONS: A semiautomated method based on a morphologic analysis was developed. Its application was found to be useful in the discrimination of GBM from solitary MET.
22
Handbook of Chemometrics and Qualimetrics, Part B
Eric R. Ziegel · Technometrics · 2000 · 466 citations
An Integrated Computational/Experimental Model of Tumor Invasion
Hermann B. Frieboes, Xiaoming Zheng, Chung-Ho Sun et al. · Cancer Research · 2006 · 298 citations
Medicine, Cancer Biology, Oncology +17